• Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies

    January 16, 2017, Stockholm: Redwood Pharma AB (publ) has now according to plan completed optimization work surrounding the manufacturing process of RP101 that is needed for the coming safety studies. RP101 represents the combination of the company’s active substance and the IntelliGel® drug delivery platform. Production of RP101 for the safety studies will now begin. […]

  • Development of Redwood Pharma’s RP101 ophthalmic therapy continues according to plan along with value-enhancing networking

    The pace of Redwood Pharma development activities surrounding the company’s dry eye ophthalmic therapy RP101 has been high during the fall of 2016. Our spring IPO on AktieTorget where the company raised SEK 15 million has intensified development of RP101 while the firm has not experienced any setbacks. This has enabled the company to participate […]

  • Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer

    Redwood Pharma AB (publ), a company that develops pharmaceuticals within ophthalmology, announces today that Ulf Björklund has accepted the company’s offer to become Chief Medical Officer (CMO). In this role, Ulf Björklund will oversee clinical development of the Company’s new product candidate RP101 a therapy to treat chronic Dry Eye Disease in post-menopausal women. The […]

  • Market Trends Highlighted in Tear Film and Ocular Surface (TFOS) Conference in Montpellier Confirm Need for Redwood Pharmas Dry Eye Therapy

    Women make up two thirds of those suffering from Dry Eye Disease (DED). Presentations and scientific results shown at TFOS, which was held between Sep. 7-10 in Montpellier, demonstrated that sex should be considered as a biological parameter, as well as encouraged researchers to better understand the unique needs of women. By focusing on women’s […]

  • Japanese patent granted for IntelliGel platform

    The granting of a Japanese patent for the IntelliGel® platform opens a significant global market within ophthalmic medicines to Redwood Pharma. It is estimated that the total Japanese market in 2014 for prescription ophthalmic medicines was valued at USD 3.2 billion[1]. Redwood Pharma has now strengthened its commercial possiblities to exploit this market. Redwood Pharma […]

  • Redwood Pharma to present at French-Swedish Life Science Day 2016

    On October 20th, Redwood Pharma AB (publ.) will present at the French-Swedish Life Science Day organized by Business Sweden, the Swedish Embassy and strategic partners at the Swedish Embassy in Paris.  The conference will gather early stage and highly innovative medical technology and biotechnology companies from Sweden and France. European life science investors as well […]

  • Redwood Pharma to attend leading conference on ocular tear film science

    The 8th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance will occur from September 7-10, 2016 in Montpellier, France. This Conference is sponsored by TFOS ( and is designed to assess the current knowledge and ‘state of the art’ research on the structure and function of the tear film […]

  • Redwood Pharma attending OIS-ASRS Conference in San Francisco

    Redwood Pharma attending OIS-ASRS Conference in San Francisco Redwood Pharma AB (publ) announces that it will be attending the Ophthalmology Innovation Summit-American Society for Retina Specialists (OIS-ASRS) in San Francisco, California, USA on August 8, 2016. The summit will focus on innovative treatments for back of the eye or retinal diseases. One of the more […]